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Cardiovascular diseases (CVDs) remain the leading cause of death globally. In addition to conventional medications, a
plethora of herbal products continue to offer therapeutic alternatives to patients to assuage suffering. Nonetheless,
concomitant administration of herbs and conventional medicine are not always safe which could mimic, oppose or
magnify the effect of the latter leading to serious herb-drug interactions, most of which escape pharmacovigilance. The
paucity of relevant information to clinicians in relation to herb-drug interactions, the inadequacy of evidence-based
knowledge coupled with the lack of mechanistic facts poses a momentous threat to meet desired therapeutic outcomes in
CVD patients. In this endeavor, key scientific databases have been explored to review common herbal products that might
interfere clinically with conventional drugs used for CVDs and related complications. Ten common medicinal plants have
been included and representative case reports whereby herbal products are thought to be inducers of adverse events are
also discussed. It is anticipated that the present review will be a pinnacle of evidence and hence serve as an up-to-date
fundamental repertoire of recent scientific findings to promote better understanding of adverse herb-drug events amongst
clinicians and enhance rapport between clinicians and patients for subsequent counseling. Indeed, acknowledging the risks
attributed to herb-drug interactions is fundamental in the management of CVDs and related implications which should not
be underestimated or considered as trivial by both health-care professionals and herbal consumers.
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Cardiovascular diseases (CVDs) are the leading cause of
death globally [93]. A recent bulletin from the World Health
Organization (WHO) in 2013 estimated that 17.3 million
people died from CVDs and it is forecasted that by 2030
mortality figures will reach 23.3 million [83]. The underlying
pathology of CVD is atheromatous vascular disease, result-
ing in a plethora of other disorders such as coronary artery
disease (CAD), cerebrovascular disease, peripheral vascular
disease, and the subsequent development of heart failure
and cardiac arrhythmias [80]. Obviously, the most opted
treatment for CVDs remains conventional drug therap-
ies for example diuretics, vasodilators, anticoagulants,
antiplatelet agents and β-blockers [93].* Correspondence: f.mahomoodally@uom.ac.mu
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in any medium, provided the original work is pA plethora of herbal products are employed routinely
by patients to manage and/or treat chronic cardiovascular
conditions and related complications [12]. There is no
denying to the blatant fact that the use of herbal products
for prophylactic and curative purposes is thriving world-
wide with the strong perception that natural products are
safe and with minimal side effects. Indeed, a recent report
from the WHO showed that 80 % of the emerging world’s
population still relies on natural products from traditional
medicine for healing [83]. Interestingly, more than 2000
plants have been documented to be used in traditional
systems of medicine and some of these are providing
comprehensive relief to the people suffering from CVDs
and related complications, specially hyperlipidemia and
ischemic heart disease amongst others [4, 12].
A multiplicity of plant based extracts are currently
approved for use in a number of developed countries.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ginseng root and St John’s wort in Germany, and Matri-
caria chamomilla, Hypericum perforatum and Plantago
major in France [3]. Nonetheless, in developing coun-
tries there is a dearth of policies that regulate the sale of
herbals. Furthermore many herbal extracts are sold as
dietary supplements in many countries bypassing pol-
icies in place for their regulation [6].
Additionally, a wealth of literature has emerged that
tend to suggest that the concomitant use of herbal prod-
ucts and conventional medicines gives rise to serious
herb-drug interactions. Indeed, it is hypothesized that
the likelihood of such interactions is increased in pa-
tients employing drugs with a narrow therapeutic index
for example; warfarin, cyclosporin and digoxin. The
majority of cases reported have been initiated by the
alteration of drug metabolism carried by the Cyto-
chrome P450 enzyme system triggered by another co-
administered drug, food or natural product [16, 31].
Interestingly, herb-drug interactions have been postu-
lated to raise or lower the pharmacological or toxico-
logical effects of any of the components inducing the
interaction [60].
Moreover, panoply of factors complicate the use of
herbal medicines and have been identified as; lack of
scientific evidence of safety and efficacy, regulatory over-
sight, quality control and knowledge regarding herb-drug
interactions amongst users and health-care providers. In
addition, under-reporting of adverse events leads to an
underestimation of adverse effects and subsequently the
failure for many countries to adopt a reliable pharma-
covigilance system [65]. Likewise, studies from Nigeria,
Kuwait, United Arab Emirates, Oman and Australia have
shown that health care professionals, in particular phar-
macist’s knowledge was poor when it came to evaluate
the side effects and interaction profiles of the herbal
products they supplied. Additionally there is a dearth in
mechanistic knowledge that governs alteration in me-
tabolism of a drug by another one, in particular herbal
products and few systematic reviews have been gener-
ated to help clinicians in devising better counseling
strategies [37, 38, 65, 75, 81].
To this effect, the present review endeavors to over-
view up-to-date information on common herbs used for
CVD and emphasize on potential drug-herb interactions
in CVD patients. It is anticipated that the present com-
pilation will contribute towards raising awareness among
health care professionals as well as herbal-products con-
sumers on various herbs that may induce unexpected
side effects and/or result in severe drug-herb interac-
tions in CVD patients. In this endeavor, major scientific
databases such as EBSCOhost, PubMed Central, Science
direct and Emerald amongst others have been probed
with key terms “cardiovascular drugs,” “herbal productsfor CVD”, “complementary therapies,” “herb-drug inter-
action,” and “cardiovascular disease interactions” to
identify citations, abstracts, medicinal case reports and
articles on herbal products and CVDs and related com-
plications. Abstracts and titles were evaluated for rele-
vance. Case reports, case series, validated mechanisms,
interaction effects, and basic science research were in-
cluded. Publications not relevant to the discussion of
herbal products for CVDs were excluded. Ten medicinal
plants (Aconitum spp., Allium sativum, Citrus paradisi,
Cratageus spp., Ephedra sinica, Ginkgo biloba, Ginseng,
Hypericum perforatum, Leonurus cardiaca, and Stepha-
nia tetrandra) were included in the present review to-
gether with a number of case reports.
Herbal medicines and CVDs
Herbal medicine, also known as phyto-remedies has
always been involved in assuaging human suffering since
time immemorial and its use is still burgeoning world-
wide. This surge in interest relates to the inability of
modern medicine to successfully address the chronicity
of many modern illnesses. Indeed, the scientific commu-
nity can no longer ignore the worldwide exponential
surge in public enthusiasm for disease management
through the use of herbal products as more than half of
FDA-approved drugs are natural products or derivatives.
Panoply of reports have established the fact that patients
with chronic diseases such as insomnia, chronic fatigue
and CVD tend to use herbal therapies to manage their
ailments [81].
Herbal medicine contain a multiplicity of biologically
active natural products from which various drug leads
that have/are being derived for the development of com-
mercial drug preparations. For example, ephedrine from
Ephedra sinica (ma-huang), digitoxin from Digitalis pur-
purea (foxglove), salicin (the source of aspirin) from
Salix alba (willow bark), and reserpine from Rauwolfia
serpentina (snakeroot) amongst others. Likewise, a num-
ber of herbal products have been employed worldwide
for the management of CVD and this culture has been
passed on to the modern generation [37].
However, it is estimated that 70 % of individuals who
use herbal medications do not report such practice to
their prescribers and pharmacists. For instance, when-
ever cases of side effects have been reported, allergic re-
actions and toxic-effects of the concomitant intake of
herbal products with drugs have been observed. Add-
itionally, it was found that the acquaintance of health
professionals to such events was poor. The lacuna of
such knowledge exposes a large percentage of individ-
uals to the possible adverse effects from herb-drug inter-
actions and other potential side effects [81].
Unless practitioners and health authorities develop ap-
propriate approach including pharmacovigilance tools to
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concomitant use of herbs; monitoring and recognizing
drug-herb interactions will still remain a major barrier
in patient’s care [41]. Physicians-patients communication
should be enhanced and the former must be ready to
investigate about patient’s use of herbs in a non-
judgmental approach, which otherwise will only prompt
patients hide valuable information. Indeed, patients
should be treated as a partner and the use of herbs
must not be made unconventional [12].
The nature of herb-drug interactions
In general any orally administered drug has to pass
through the protective line of cytochrome P450 enzymes
(CYP450) and transport proteins before making its way
to the bloodstream; this constitutes the first-pass effect.
The diversity of cytochrome isoenzymes is vast and hence
depicted by a specific nomenclature bearing Arabic nu-
merals. Among the isoenzymes 3 families (CYP1, 2 and 3)
have been identified to exert a pivotal role in drug me-
tabolism and are concentrated in the liver and the in-
testine. Moreover, drug metabolism is a never ending
process whereby every second drug is metabolized by
isoenzyme Cytochrome P3A4 (CYP3A4). Additionally,
there is mounting evidence that alteration of the 170 kDa
phosphorylated glycoprotein; p-glycoprotein (p-gp) - a
major transmembranous efflux transporter of the intes-
tinal mucosa plays a crucial role in herb-drug interac-
tions. Nonetheless, secondary metabolites found in
plants have the potential to alter the first-pass effect
since some of them can mimic substrates for enzymes
and transport proteins. The result of these effects gives
rise to herb-drug interactions [51]. Two types of inter-
actions exist:
1. Pharmacokinetic herb-drug interactions (PKHDI) arise
whenever the absorption, distribution, metabolism or
elimination of one drug is modified by another one. In
this case the hepatic metabolism of drugs is altered
due to actuation or suppression of primarily the
CYP3A4 isoenzyme of the CYP450 family. The
effects of these changes have the potential to induce
important clinical consequences [5].
2. Pharmacodynamic herb-drug interactions (PDHDI)
are the result of the change in effect of a drug
by another one. A wide diversity of clinically relevant
pharmacokinetic interactions are due to modifications
of CYP450 system; transmembrane pump, hepatic or
renal insufficiency, as well as mechanisms still being
elucidated. PDHDI may be:
(a)Additive or synergistic: the administration of
more than one drug having the same
pharmacological effects together augments their
desired as well as side effects. For example, whenmethotrexate and sulfonamides are used
concomitantly there is a high risk that this
combination precipitates megaloblastic anaemia
due to the antifolate effect of both agents.
(b)Antagonistic: the concomitant use of two
pharmacological agents decreases the effect of one
or both agents. This can be epitomized by a loss of
glycemic control in diabetic patients whenever
systemic corticosteroids and oral hypoglycaemic
agents are administered in combination [74].
Aconitum spp. (Ranunculaceae)-Monkshood root
The use of the Aconitum species, such as A. kusnezoffii
and A. carmichaeli is commonly advocated by traditional
Chinese Medicines (TCM) practitioners for the manage-
ment of pain caused by trigeminal and intercostal neur-
algia, rheumatism, arthritis, bruises, and fractures. The
major metabolites isolated form the plant up to date in-
clude diterpenoid ester alkaloids, including aconitine.
Interestingly, it is hypothesized that these constituents
are responsible for a major number of deaths from car-
diovascular collapse and ventricular tachyarrythmias in
Hong Kong and Australia. It has been established that
the alkaloids activate sodium channels and excite car-
diac, neural and muscular tissues above normal levels.
Furthermore, they have the potential to induce mild dia-
phoresis and can slow pulse rate due to its effect on
brainstem centers and direct effects of aconite on the
myocardium may result into ventricular fibrillation.
Additionally, a number of side effects including brady-
cardia, hypotension to fatal ventricular arrythmia can
arise due to contact with leaves or sap from Aconitum
plants [28].
Allium sativum (L.) (Alliaceae)-Garlic
Allium sativum is probably one of the earliest known
medicinal plant exploited as a versatile medicinal plant
employed for the prophylaxis, management and treat-
ment of many disease conditions in man. Its basic prop-
erties make it a valuable plant for the prevention of
hypercholesterolaemia, hypertension, artherosclerosis as
well as cancer. Garlic is also known to be an antimicro-
bial and it is exploited by a number of communities
around the world as an immune booster. Amongst the
plethora of metabolites that the garlic plant synthesizes
up to date only a few have been shown to exhibit
therapeutic properties and have been identified as
organosulfur compounds and named as allicin, alliin
and ajoene [17].
The interaction of A. sativum supplements with anti-
hypertensive, anticoagulant, antiplatelet and antilipi-
demic drugs is well documented. It is hypothesised that
A. sativum metabolites bear configuration that can exert
agonist and inhibitory effects similar to these drugs on
Table 1 The effect of grapefruit on the AUC of drugs employed
in cardiology
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and toxic potential [12]. During a randomized trial
where subjects were administered three preparations of
A. sativum versus placebo it was observed that A. sati-
vum did not significantly alter LDL-cholesterol, HDL-
cholesterol, triglycerides, or total cholesterol-HDL ratio
[53]. Moreover, studies in rats have demonstrated that
A. sativum can interact pharmacodynamically with anti-
hyperlipidaemia and antihypertensive medicines, such as
atorvastatin, propranolol, hydrochlorothiazide or capto-
pril. Moreover, a high dose of oral atorvastatin (l0 mg/
kg) has been shown to induce kidney damage if used ei-
ther alone or in combination with high concentrations
of A. sativum (1 % in the food), while low doses of ator-
vastatin (2.5 mg/kg) in combination with high concen-
trations of A. sativum (0.75 % in the food) has low
nephrotoxic potential [65]. Additionally, available data
from previous studies have depicted that bleeding from
garlic occurs in individuals ingesting large doses of garlic
which is an average consumption of four cloves daily.
Interestingly studies tend to show that ajoene is the me-
tabolite that inhibits platelet aggregation and raises by
many folds the risk of hemorrhaging in patients under
anticoagulant or antiplatelet agents. In line with this, it
is recommended that the intake of garlic supplements
should be halted for about 10 days in patients about to
undergo surgery, and this practice is of paramount im-
portance in patients under anticoagulant and antiplatelet
drug therapy [73].
Citrus paradisi Macfad. (Rutaceae) - Grapefruit
Citrus paradisi is a food plant high in pectins and
lycopene hence used as a dietary intervention to lose
weight and improve cardiovascular health. Its bioactive
constituents, namely naringenin and bergamottin have
been reported to inhibit the CYP3A4 enzyme in small-
intestine enterocytes [1]. This results in an increase in
the area under the curve (AUC) in blood of CYP3A4
substrate drugs. A plethora of conventional drugs are
metabolized by the CYP3A4 system and include mainly
calcium channel blockers, cyclosporine, statins, midazo-
lam, estrogen, and terazosin. Additionally, the bioavail-
ability of these medications is increased and their effect
is potentiated which results into dangerous hypotension,
myopathy, or liver toxicity. A study carried out on post-
menopausal women taking estrogen has shown that
grapefruit juice may increase the risk of breast cancer by
inhibiting estrogen metabolism by CYP3A4 [5]. A num-
ber of drugs have been found to interact with grapefruit
juice and it has been established that it is an average
daily consumption of 227 g of grapefruit juice that will
suppress the activity of cytochrome enzymes and that
the concomitant use with cardiovascular drugs such as
antiarrhythmic drugs will result into cardiotoxicity,bradycardia and liver injury. When taken with calcium
channel blockers it can cause tachycardia as well as per-
ipheral edema. It is recommended that patients under
cardiovascular drug treatment should not consume
grapefruit for about 24 to 72 h prior to drug use [54]. A
number of reports tend to show that many antilipidemic
agents mostly artorvastatin, lovastatin and simvastatin
interact with the herb. Additionally it has been established
that a considerable number of drugs employed in the
management of cardiovascular disease such as carvedilol,
felodipine, nifedipine, nisoldipine, nicardipine, nitrendipine,
nimodipine and verapamil also interact with grapefruit juice
[41, 61, 66] are summarized in Table 1 [24]. Interestingly,
it has been shown that the herb can also interfere with
the absorption of several drugs and results in a reduced
plasma concentration of fexofenadine and the beta-blockers
celiprolol and talinolol has been found in patients [54].
Cratageus spp. (Rosacea) - Hawthorn
Hawthorn extract has a long standing traditional use in
treating panoply of disorders including anxiety, asthma,
hypertension, dyslipidemia, hypotension, angina, arrhyth-
mias, heart failure, and indigestion. Interestingly, the most
revealing data from the plant advocates positive benefits
in chronic congestive heart failure patients (CHF) [9].
Based on existing studies carried on rats fed on a hyer-
lipidemic diet, Crataegus extract has been found to in-
hibit the scale up of cholesterol, triglycerides, and
phospholipids in LDL and very low-density lipoprotein
ultimately preventing the manifestation of atheroscler-
osis. In addition, extracts of Cratageus spp. can induce
positive inotropic and exert vasodilatory effects increas-
ing myocardial perfusion and reducing afterload. Inter-
estingly, when used as a complementary therapy for
CHF, the plant has been effective in relieving the pa-
tient’s symptom as well as improving physiologic out-
comes [49]. Cratageus can potentiate the activity of
digitalis hence, its concomitant use with the drug has to
be monitored carefully. Given the hypothesis that Cratae-
gus spp. can enhance the activity of digitalis, the single
Suroowan and Mahomoodally Clinical Phytoscience  (2015) 1:1 Page 5 of 13study involving both agents in humans found out that
the pharmacokinetic profile of digoxin does not differ
with or without concomitant hawthorn use. Further-
more, these findings can be corroborated with the re-
sults from a systematic review carried on 5,577 patients
reporting that adverse events due to hawthorn were not
significant in nature and no drug interaction reports or
deaths were reported [5].
According to another study, employing high doses of
Crataegus extract induces a cardioprotective effect on
ischemic-reperfused heart while not interferring with the
coronary blood flow. Conversely, other studies carried
out in cats and dogs administered oral and parenteral
oligomeric procyanins of Crataegus showed an increase
in coronary blood flow. Furthermore, double-blind clin-
ical trials have demonstrated simultaneous cardiotropic
and vasodilatory actions of Crataegus as well as its po-
tential to lower blood pressure as part of its action in
lowering peripheral vascular resistance [63, 78]. Given
this insufficiency of data on the reported safety and effi-
cacy of the plant health care professionals are strongly
discouraged to promote use of the plant’s extract in pa-
tients prescribed with heart failure medications [7, 57].
Ephedra sinica Stapf. (Ephedraceae)- Chinese ephedra or
Ma huang
Ephedra sinica has a long standing use in TCM to treat
respiratory symptoms and febrile illness. This plant has
been in extensive use in TCM as an anti-asthmatic and
decongestant for 5000 years [11]. In addition, E. sinica,
also referred to as Chinese ephedra or Ma Huang, was
in common use as a performance enhancer, fat burner,
and to manage weight before its prohibition from the
United States in April 2004 due to serious adverse ef-
fects such as lethal arrhythmias, stroke, vasoconstriction,
and myocardial infarction [11]. A multiplicity of dietary
supplements containing E. sinica are still in popular use
in many western countries despite their prohibition by
the Food and Drug Administration in America [11].
The alkaloids of the plant are the main active ingredi-
ent of E. sinica. These alkaloids show both direct agon-
ism at the adrenergic receptors as well as indirect
agonism by stimulating the release of norepinephrine
from presynaptic neurons [11]. Clinical results involve
tachycardia, hypertension, diaphoresis, bronchodilation,
agitation, and mydriasis with a retained light reflex.
These sympathomimetic effects have been suggested to
be responsible for the reported adverse events in human
and mortality in animal studies [11].
During the past decade, the FDA has identified more
than 100 ephedra containing products that have been pos-
tulated to be the cause of more than 800 reports of adverse
reactions. A plethora of adverse reactions reported included
insomnia, nervousness, tremor, headaches, hypertension,seizures, arrhythmias, heart attack, and stroke as well as le-
thality [11]. Moreover a case report of myocardial infarction
in a 29-year-old patient following ephedrine use exemplifies
the long-term danger of such products and is the first re-
port of coronary artery aneurysm associated with its use
[14]. Due to deleterious effects on the cardiovascular sys-
tem, the FDA proposes a maximum daily dose of 24 mg
with equal intake every 6 h. This rule also specifies that la-
bels should be attached ephedrine-containing products spe-
cifying its use for no more than 7 days and warning
consumers that exaggerated intake of the product may re-
sult in heart attack, stroke, seizure or death [11].
Ginkgo biloba L. (Ginkgoaceae) - Ginkgo
Ginkgo biloba commonly called the maidenhair tree is
one of the oldest living fossil on the planet dating well
over 200 million years. G. biloba forms part of one of
the most popular herbs used worldwide and is advocated
mainly for cerebral insufficiency, memory loss, Alzhei-
mer’s disease, peripheral vascular disease and circulatory
disorders [28]. The use of the root and kernels of G.
biloba is widely documented in TCM.
A number of scientific reports tend to support the
fact that G. biloba extract is primarily employed against
cerebral insufficiency and exerts secondary effects on
vertigo, tinnitus, memory, and mood. Similarly, an in-
vestigation on 327 demented patients showed that
120 mg of G. biloba extract produced improvements in
dementia [69]. Despite the fact that Ginkgo is now an
accepted drug in Europe, it is still considered as a diet-
ary supplement in the United States available in 40-mg
tablets of extract. In Europe, the recommended max-
imal daily dose of the plant’s extract is 120 -mg where a
40-mg tablet is taken three times with meals. Multiple
adverts effects from G. biloba extract have been reported
and include gastrointestinal disturbances, headache, and
skin rash. Several case reports of bleeding, including
subarachnoid hemorrhage, intracranial hemorrhage, and
subdural hematoma, have been associated with G.
biloba [30, 40, 67, 77].
A concentrated extract of G. biloba leaves was devel-
oped in the West in the 1960s. Many of its secondary
metabolites have been identified and named for e.g.
quercetin, kaempferol, isorhamnetin and terpene trilac-
tones. Interestingly, other metabolites from the plant
such as ginkgolides and bilobalides have been found to
have antiplatelet activity and hence its concomitant use
with anticoagulant agents such as warfarin and heparin
as well as analgesic agents such as aspirin, triclopidine
and clopidogrel is not recommended. Additionally, a
combination of ginkgo with antiplatelet agents, anticoagu-
lants or antithrombotics results in hyphema, subphrenic
hematoma as well as intracranial hemorrhage [43, 45].
Interestingly, it has been found in clinical trials that the
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the levels and lowers the effectiveness of drugs metabolised
by this enzyme such as like nicardipine [73].Panax quinquefolius (L.) and Panax ginseng C.A.Mey.
(Araliaceae) - American ginseng and Asian ginseng
The use of Ginseng as an herbal medicine dates now
more than 2000 years in China, Korea and Japan, and it
is only in the last twenty years or so that it has gained
popularity in the United States, Canada and Europe.
Ginseng varieties have been garnering increasing interest
recently for their effects on the cardiovascular system.
Its major active components are ginsenosides and up to
date the structure of about 40 distinct ginsenosides has
been elucidated. Indeed, ginseng possesses diverse
pharmacological effects including immune modulation,
anti-diabetic and anti-cancer effects. Interestingly, in the
cardiovascular system, ginseng has been found to trigger
nitric oxide release, vasorelaxation, improve lipid pro-
files, and has been used as a treatment for hypertension
and heart failure [20, 33, 40, 71, 90, 94].
Two species namely Panax quinquefolius and Panax
ginseng are considered to harbor significant therapeutic
outcomes. Chemically, more than one factor differenti-
ates P. quinquefolius and P. ginseng. One important par-
ameter that differentiated the two is the presence of
ginsenoside Rf in P. ginseng versus the presence of pseu-
doginsenoside F ll in P. quinquefolius [59]. Compared
with the long standing use and the widespread research
on P. ginseng, data on P. quinquefolius is relatively
limited. Ginseng abuse syndrome includes hypertension,
behavioral changes, and diarrhea. Ginseng can mimic es-
trogen effects since its active component ginsenosides
shares a similarity with the chemical structure of testos-
terone, estrogen, and glucocorticoids. This points to the
fact that Ginseng should therefore not be employed by
pregnant women and or receiving hormone replacement
therapy. Furthermore, neonatal death has been linked to
the maternal use of the plant. In cardiology, the con-
comitant administration of ginseng with warfarin has the
potential to reduce prothrombin time [73].
A number of studies have emphasized that P. quinque-
folius has a multiplicity of pharmacological effects on
the cardiovascular and central nervous systems, antidia-
betic effects, antitumour activities and immunomodula-
tory effects similar to those of P. ginseng. In comparison
to P. ginseng, ginsenosides are also its major biologically
active constituents. In a study involving 20 healthy indi-
viduals it was found that P. quinquefolius reduced the
anticoagulant effect of warfarin after 14 days of its
administration [59]. Similarly, in another study, a dose
of 2 g per day for 14 to 28 days of American ginseng
caused a decrease in the AUC of warfarin [36].P. ginseng is a medicinal herb documented with di-
verse biological effects, including immune function en-
hancement and anti-aging, anti-diabetic, anti-tumor,
anti-apoptotic, and anti-oxidative effects. Indeed, a wealth
of literature suggests that it has diverse pharmacological
activities, including effects on the central nervous system,
antineoplastic effects and immunomodulatory effects.
Many of ginseng’s medicinal effects are attributed to tri-
terpene glycosides, which are known as the ginsenosides.
Indeed, 38 ginsenosides have been found to bear the po-
tential of exerting distinct effects on the endothelial cells,
prevention of programmed cell death, regulation of angio-
genesis, and stabilizing blood pressure. Intriguingly, it is
reported that ginsenosides can enhance endothelial func-
tion [29, 47]. Additionally it is also reported that P. ginseng
can induce the activity of the enzymes of the CYP450 fam-
ily and as a consequence lower the bioavailability of a
number of drugs including warfarin [26]. A number of re-
ports have also concluded that P. ginseng bears the same
effect as anticoagulant drugs in where it reduces platelet
adhesiveness and binding as well as delays the time re-
quired for blood to clot. When administered concurrently
with warfarin it has the potential to lower the drug’s level
during metabolism where reduced levels of the drug
lowers it INR (international normalized ratio) [62, 94].
Nonetheless, even with these set of findings it has not
been possible to fully understand the mechanism under-
lying these consequences. It is only known that the herb
has no effect on the activity of CYP1A2 and CYP3A4 but
induces CYP2C9 the enzyme primarily responsible for
S-warfarin metabolism but nothing has been yet confirmed
for other isoenzymes of the cytochrome family [22].
Hypericum perforatum L. (Hyperiacea) - St John’s Wort
Hypericum perforatum remains one of the most ancient
and popular herbs in the United States [39]. It is mainly
advocated against depression, anxiety, sleep disorders,
the common cold, herpes, and the human immunodefi-
ciency virus. Furthermore, it is used as a topical anal-
gesic, and is administered as an enema for the treatment
of ulcerative colitis. Scientific investigations have identi-
fied numerous pharmacologically active compounds in
the plant including; naphthodianthrones for example hy-
pericin and pseudohypericin, phloroglucinols for example
hyperforin and adhyperforin, flavonoids for example quer-
cetin, quercitrin and 13, 118-biapigenin [65].
H. perforatum has been identified as an inducer of the
CYP450 system, particularly of the main drug metaboliz-
ing enzyme CYP3A4. Ultimately it results in decreased
levels of various drugs metabolized by this enzyme sys-
tem such as; ethinyl estradiol, indinavir, and cyclosporine
with the potential of reducing their levels up to 50 % as
happened in an organ transplant patient under cyclo-
sporine treatment resulting in tissue rejection. Given the
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such as arrhythmia, hypertension, or other undesirable
effects its co-administration with drugs metabolized by
CYP3A4 system should be prohibited [13].
It has also been found that the concomitant use of
warfarin with H. perforatum decreases blood clotting
time hence resulting in sub-therapeutic anticoagulation
and increased risk of thromboembolism [92]. Indeed, pa-
tients under warfarin treatment and who have a history
of stroke, thrombosis, atrial fibrillation, or prosthetic
cardiac valves should avoid the use of St John’s Wort.
Sub-therapeutic levels of statins may potentiate the risk
of cardiovascular events. The herb can also induce the
multidrug resistance gene product P-gly, which may re-
duce the blood levels and efficacy of drugs such as di-
goxin [8, 27]. Additionally, it has been reported that the
herb can induce the activity of CYP2C9 as well and result
in decreased levels of drugs metabolized by this enzyme.
Indeed, the inability of warfarin and phenprocoumon to
exert their therapeutic potential as a consequence of de-
pleted blood levels has been reported and is considered a
confirmed interaction with the herb. Therefore, the UK
Medicines and Healthcare Regulatory Agency forbids
CVD patients from using the herb [81]. Additionally it is
reported that the levels of drugs used for the management
of cardiovascular drugs such as amiodarone, amlodipine,
diltiazem, felodipine, lidocaine, losartan, lovastatin, nifedi-
pine, propafenone, simvastatin, and verapamil are severely
reduced during concurrent use of the herb hence prevent-
ing the desired response from these drugs. The concomi-
tant use of these herbs with drugs can hence exacerbate
conditions like arrhythmia, angina pectoris, or hyperten-
sion [8]. Table 2 summarise the major classes of drug and
the Cytochrome enzyme/transport protein involved dur-
ing the adverse event.
Leonurus cardiaca- Linn. (Lamiaceae)-Motherwort
Motherwort has a long standing use in orthodox medi-
cine particularly among the European and Asian trad-
itional systems. Its use as a sedative and antispasmodic
started earlier than the 15th century. The origin of itsTable 2 Summary of major classes of drug and the Cytochrome







AUC by 25-30 %
Nifedipine/calcium
channel blocker
CYP3A4, P-gp Decreases drug




AUC by 50 %
Warfarin/
anticoagulant
CYP2C9 Loss of efficacy due
to decrease in INR
Adapted from [23]name emanates from its use by Greeks for the relief of
anxiety among pregnant women. Its potential against
cardiovascular ailments is also well documented where it
can assuage cardiac arrhythmias, tachycardia as well as
heart palpitations. Its main metabolites elucidated till
date are the phenylpropanoid glycosides and contribute
to the purported pharmacological effects. Studies in rats
have depicted that a phenylpropanoid, lavandulifolioside
isolated from the herb has the potential to extend PR,
QRS, and QT intervals. It is also validated that the activ-
ity of the herb can be compared to that of class 3 antiar-
rhythmic agents. Despite considerable research on this
herb there is a dearth in evidence regarding its safe and
effective use in the management of palpitations and car-
diac arrhythmias in humans. Additionally data related to
the metabolism of its active constituents by the CYP450
family is scarce. In line with the results of studies involv-
ing this herb, it is suggested that its use must be moni-
tored carefully in patients who are under drug treatment
bearing narrow therapeutic windows as well as metabo-
lized by the cytochrome isoenzymes. Additionally, an
intravenous infusion of the herb has antiplatelet and an-
tithrombotic effects as well as depletes fibrinogen levels.
Due to these effects its concomitant use with antiplatelet
or anticoagulant agents is strongly interdicted [8, 73].Stephania tetrandra - S. Moore (Menispermaceae)
Stephania tetrandra is recommended for hypertension
and angina in TCM. One of the major metabolites of the
plant responsible for blood pressure lowering effect is
the alkaloid tetrandrine which acts as a T and L calcium
channel antagonist similar to verapamil and hence when
taken concomitantly competes with the drug and other
calcium channel blockers for the same effect. Animal
studies in rats have demonstrated that a parenteral infu-
sion of dose 15 mg/kg has the potential to lower the
mean, systolic, and diastolic blood pressures for more
than half an hour. Nonetheless, a higher dose of the in-
fusion (40 mg/kg) caused death of the rats by myocardial
depression. Moreover in dogs an orally administered
dose of 40 mg/kg 24 times at regular intervals for 60 days
caused necrotic liver cell death while the same experiment
at a lower dose of the tetrandrine (20 mg/kg) caused re-
versible injury to liver cells. The use of the herb is not rec-
ommended due to underlying risks of hepatotoxicity and
renal failure unless more extensive studies establish safe
and effective doses of the alkaloid [15, 73].Miscellaneous plants and CVD
A summary of some herb-drug interactions and other
herbal products documented to have adverse effects is
presented in Tables 3 and 4.
Table 3 Mechanism of herb-drug interactions





Venous insufficiency SM aesculin a hydroxycoumarin; ↑ anticoagulants. A, I [2]
Aloe barbadensis/aloe vera Laxative,
hypercholesterolemia
Laxative; causes hypokalemia: ↑ cardiac glycosides and
antiarrhythmic drugs.
I [82]
Ammi visnaga/khella Muscle spasms SM khellin; inhibits cytochrome P 450 enzymes:
anticoagulants ↑, calcium channel blockers.
Not known [85]
Angelica sinensis/angelica Antitumour, antiinflammatory,
analgesic, antispasmodic,
dyspepsia, infection
Decreases prothrombin time ↑; anticoagulants, calcium
channel blockers.
A [88]
Cassia senna/senna Laxative Causes hypokalemia; ↑ cardiac glycosides + antiarrhythmic
drugs and calcium channel blockers.
I [84]







Inhibits CYP3A4 Not known [42, 76]
Glycyrrhiza glabra/licorice Gastric ulcers Causes hypokalemia reduces water and sodium excretion ↑;




Anti-inflammatory Inhibits cytochrome P 450 enzymes mainly CYP1A2 and






Inhibits cytochrome P 450 enzymes mostly CYP3A4 and





Menopausal symptoms Inhibits platelet activating factor; anticoagulants Unknown [87]
Zingiber officinalis/ginger Antiemetic Inhibits thromboxane synthase, acts as a prostacyclin agonist
and large doses enhance hypothrombinaemia ↑; platelet
inhibitors, anticoagulants and antihypertensives.
A [89]
Key:↑; Induces effect of ↓; Suppresses effect of, A agonism, SM secondary metabolite, I inhibition, Anta antagonism
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It is imperative that information on the risks associated
with the use of herbal products is systematically col-
lected and analysed in order to protect public health. A
number of cases of herbs interacting with cardiovascular
drugs have been reported [10].
Camellia sinensis (L.) kuntze (Theaceae) -Green tea
The consumption of Camellia sinensis as a medicinal
herb began almost 5000 years back. Today, it is one of
the most popular beverages worldwide. Plethora of
chemical components have been isolated from the plant
including chiefly polyphenols, catechins, caffeine, amino
acids, and flavonoids and reported to have anti-oxidant
properties having many beneficial effects. Interestingly,
tea flavonoids have been reported to reduce inflamma-
tion, possess antimicrobial effects and prevent tooth
decay. Furthermore the consumption of C. sinensis may
have diuretic effects due to the caffeine present. Theo-
phylline, a licensed medicine for the treatment of re-
spiratory diseases such as asthma is one of the
components of the C. sinensis [64]. There is mounting
evidence about the benefits of C. sinensis in maintaining
endothelial function and vascular homeostasis and anassociated reduction in atherogenesis and CVD risk. C.
sinensis catechins have been suggested to improve vas-
cular function from epidemiological, human intervention
and animal studies [48]. Nonetheless, it is reported that
a 44 year old male patient with an artificial heart valve
having recourse to one gallon of green tea daily and
under warfarin treatment had a reduced response to the
drug and when examined it was found that the INR of
the drug was reduced from 3.79 to 1.37 [18].Citrus aurantium (L.) (Rutaceae)-Bitter orange
Citrus aurantium is also commonly known as Aurantii
pericarpium, Kijitsu, Shangzhou zhiqiao, Zhi qiao, Zhi
shi, and Seville orange. C. aurantium extract and its
primary protoalkaloidal constituent p-synephrine are
extensively used in weight management products and as
thermogenic agents [21]. Other widely known uses are
enhancing stamina in athletes. C. aurantium extract is
widely known as C. aurantium extract, a product that is
derived from the immature green fruits of the Seville or-
ange. C. aurantium is a small citrus tree, about 5 m tall,
with scented white flowers. C. aurantium is too sour to
be popular for eating, but the ripe fruit is eaten in Iran
Table 4 Summary of common herbs used in CVD with possible adverse events
Scientific/vernacular name Ethnopharmacological use Possible adverse event Likely nature
of effect
Reference
Capsicum annuum/capsicum Shingles, trigeminal and diabetic
neuralgia
Blood pressure increased with mono-amine
oxidase inhibitors
Not known [17]
Capsicum spp./chilli pepper Analgesic May interfere with antihypertensives I [12]
Convallaria majalis/ lilly of the valley CHF β-blockers + calcium channel blockers + digitalis +
quinidine + steroids
Not known [17]
Cucurbita pepo/pumpkin seed Benign prostatic hyperplasia Diuretics A [12]
Fumaria officinalis/fumitory Infection, edema, hypertension,
constipation
β–blockers + calcium channel blockers + cardiac
glycosides ↑
[17]
Gossipyum hirsutum/gossypol Male contraceptive Diuretics ↑, Hypokalemia Not known [17]
Laminariales/kelp Cancer, obesity Antihypertensives and anticoagulants ↑ Not known [17]
Medicago sativa/alfafa Arthritis, asthma, dyspepsia,
hyperlipidemia, diabetes
Warfarin ↑ Not known [12]
Aetheroleum Menthae piperitae/
peppermint oil
Irritable bowel syndrome Cardiac glycosides ↑ A [17]
Selenicereus grandiflorus/night
blooming cereus
CHF Angiotension-converting enzyme inhibitors +
antiarrhythmics + β-blockers + calcium channel
blockers + cardiac glycosides ↑
Not known [17]
Storphantus preussi/strophanthus CHF Cardiac glycosides ↑ Not known [17]
Tanacetum parthenium/feverfew Prevention of migraine Platelet inhibitors + anticoagulants ↑ A [12]
Taraxacum officinale/dandelion Laxative, diuretic Antihypertensives + diuretics ↑ A [12]
Trigonella Foenum-graecum/
fenugreek
Hypercholesterolemia anticoagulants + lipid-lowering drugs ↑ A, I [12]
Urtica dioica/nettle Diuretic, analgetic Diuretics + antihypertensives A [12]
Vaccinium myrtillus/bilberry Disturbed night vision, local
inflammation, skin conditions,
diarrhea, arthritis
Anticoagulants ↑ A [17]
Vitex agnus castus/chaste tree Menstrual symptoms Beta-blockers + Antihypertensives ↑ A [12]
Key:↑; effect induced; ↓ effect suppressed; A agonism, Anta antagonism, I inhibition, CHF chronic congestive heart failure patients
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salt and chili paste.
The most active components in C. aurantium fruit are
synephrine (also called p-synephrine or oxedrine) and
octopamine. It is the substituent for ephedra in many
ephedra free products after the latter has been banned
from the market. Interestingly, at the suggested dose C.
aurantium can increase heart rate in healthy subjects by
more than 10 beats per minute. In a study over
18 months its combined use with caffeine increased the
systolic and diastolic blood pressure of healthy subjects
increased by 10 mmHg and 9 mmHg [70]. Additionally,
health authorities from Canada recorded 15 reports of
adverse cardiovascular events by C. aurantium out of
which were serious and one even included a case of
myocardial infarction [12].
Matricaria recutita L. (Asteraceae) - Chamomille
Matricaria recutita is one of the most ancient medicinal
herbs known to mankind. It bears a rich diversity of me-
tabolites. In fact, the dried flowers of M. recutita contain
many terpenoids, coumarins and flavonoids contributingto its medicinal properties. M. recutita preparations are
commonly used for a number of ailments such as hay
fever, inflammation, muscle spasms, menstrual disorders,
insomnia, ulcers, wounds, gastrointestinal disorders,
rheumatic pain, and hemorrhoids. Furthermore, essential
oils of M. recutita are used extensively in cosmetics and
aromatherapy. Multiple preparations of M. recutita have
been developed, the most popular of which is in the
form of herbal tea consumed more than one million
cups per day [68]. A number of reports tend to suggest
that regular use of flavonoids consumed in food may re-
duce mortality from coronary heart disease in elderly
men. A study assessed the flavonoid intake of 805 men
aged 65–84 years who were followed up for 5 years. It
was found that flavonoid intake was significantly lowered
the mortality from coronary heart disease and showed
an inverse relation with incidence of myocardial infarc-
tion [19]. A reported case of M. recutita interaction with
cardiovascular drug was brought in a recent study where
a 70 year old female patient having a mechanical mitral
valve and previous episode of atrial fibrillation and under
amiodarone, digoxin, synthroid, alendronate, metoprolol
Suroowan and Mahomoodally Clinical Phytoscience  (2015) 1:1 Page 10 of 13and warfarin treatment experienced major bleeding due
to an increased INR of 7.9. This effect was induced due
to the high coumarin content which is believed to have
anticoagulant potentials as warfarin [18].
Salvia miltiorrhiza Bunge- (Lamiaceae)-Danshen
Salvia miltiorrhiza, a relative of the Western sage S. offi-
cinalis, is native to China. In TCM, the root of S. mil-
tiorrhiza has a long standing use as a circulatory
stimulant, sedative, and cooling agent. It is reported that
dihydrotanshinone present in the root of the plant can
inhibit the uptake of calcium ions in vascular smooth
muscle cells and hence exert vasorelaxant effect [52].
Additionally, in vitro studies have concluded that varying
doses of S. miltiorrhiza can interfere with platelet adhe-
sion. Interestingly, S. miltiorrhiza appears to have bene-
fits in ischemic myocardium, enhancing the recovery of
contractile force upon reoxygenation. Moreover, S. mil-
tiorrhiza has been reported to interfere with the elimin-
ation of warfarin hence increasing its blood levels as well
as inhibits cyclic adenosine monophosphate phospho-
diesterase. The result is an increase in the INR of warfarin
as well as prolongs prothrombin time hence increasing
the risks of profound bleeding [32]. It is also established
that the intake of danshen with digoxin can interfere with
the digoxin metabolism which has a small therapeutic
window and hence result in drug toxicity [73].
A number of case reports emanating from the use car-
diovascular drugs and the herb show that this practice is
not safe. Indeed a 62 year old (y/o) male who was ad-
ministered a daily dose of 5 mg of warfarin and who was
having recourse to an extract of danshen as well for
14 days had to be admitted due to pleural and pericar-
dial effusion and showed an elevated warfarin INR of
more than 8.4. Moreover, in a 48 (y/o) woman having a
daily dose of 4 mg of warfarin and concurrently taking
danshen every other day had an INR of 5.6 which is
higher than normal and which was stabilized to the
therapeutic level after danshen withdrawal. Similarly in a
66 y/o male under a 2.5 mg daily intake of warfarin was
hospitalized due to a bleeding gastric carcinoma and
when examined had an elevated INR of 5.5. Clinical tri-
als will be necessary to further evaluate the use of the
herb among cardiovascular patients since a number of
case reports have questioned its safety and efficacy [35].
Vaccinium microcarpum (Ericaceae) - Cranberry
Vaccinium microcarpum juice is a rich source of poly-
phenolic compounds, particularly anthocyanins. A num-
ber of studies have proposed that V. microcarpum
consumption might have cardioprotective effects by re-
ducing inflammation and serum lipids. Interestingly,
postprandial studies have shown increased plasma anti-
oxidant capacity following cranberry juice consumptionin healthy volunteers. An intervention trial ranging from
2 to 16 weeks have reported V. microcarpum to improve
oxidative stress, postprandial glycemic response, dyslip-
idemia, and atherosclerotic markers in healthy volun-
teers and in patients with type 2 diabetes mellitus.
Another trial involving two 12-weeks interventions in
type 2 diabetics consuming V. microcarpum juice con-
centrate powder or V. microcarpum extract powder
showed a significant decrease in serum insulin or in total
and LDL-cholesterol levels [34, 46, 50, 61, 79]. It has
been reported from a study a patient in the 70’s under
warfarin treatment for poor appetite died from gastro-
intestinal and pericardial hemorrhage. Nonetheless, mech-
anisms pertaining to such events remain unclear [18].
Discussion
Despite widespread use of herbal remedies, herb-drug
interactions are a stark reality today. The number of
cases reported for the emerging herb-drug interactions
is thriving worldwide and it is of no denying that there
is a lacuna of up-to-date documentation of herb-drug in-
teractions for CVDs. Furthermore, herb-drug interaction
events reporting amongst cardiovascular patients are
considered to be a key factor to help promote patient
health and hence ensuring successful conventional drug
therapy. It is a frequent practice for patients to judge
herbal products as safe or with minimal side effects as
they are considered to be natural and with a long history
of use. Nonetheless, there is no denying to the fact that
herbs are considered as drugs and when administered
inappropriately they can have serious adverse effects
which can even lead to mortality. In this endeavor, it is
the duty of clinicians to implement strategies that will
enable their patients to express themselves freely on any
herbal products they could be using concomitantly with
conventional drugs.
Furthermore, it is suggested that patients must be
treated as a partner in ensuring successful therapy. The
clinician must not be judgmental of the patient’s trad-
itional or cultural beliefs and must be ready to offer ap-
propriate guidance to avert the risks of adverse events
[81]. Since physicians are most of the time the first
healthcare professionals likely to encounter patients
employing herbal remedies, they need to be aware of the
plausible effects of such products as well as deleterious
effects due to interactions with drugs. They should also
be ready to use pharmacovigilance tools to document
such effects [72].
Nonetheless, in many cases the herb-drug interactions
may increase toxicity or even be fatal. This is supported
by a number of documentations where today some
mechanisms are believed to be better understood
[25]. There is evidence that taking herbal preparations
can result in pharmacokinetic or pharmacodynamic
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on conventional medicines. All pharmacokinetic interac-
tions identified so far point to the fact that herbs affect
Cytochrome enzymes and P-glycoproteins. Interactions
where herbal products can significantly increase the bio-
availability of the administered drug are more frequent
with antihypertensives, anti-coagulants, β-blockers, di-
uretics and cardiac glycosides. Plausible cases of herb-drug
interactions include bleeding when warfarin is combined
with Ginkgo biloba, A. sativum or Salvia miltiorrhiza; and
decreased bioavailability of digoxin, theophylline and
cyclosporine when these drugs are combined with St
John’s Wort [5, 74]. Patients receiving warfarin therapy
should be discouraged from using herbal products and
other dietary supplements. Raising the concentrations
of such drugs with narrow therapeutic window has
been lethal in more than one case. Indeed, it is becom-
ing increasingly evident that herbal interactions with
warfarin remains the most common case and more pre-
cautionary measures must be undertaken by clinicians
when prescribing this drug. Having a complete list of
the patient’s medical history together with discussion
about any home remedy he could be taking is also an
imperative consideration. Herbs that act in synergy
with warfarin aggravate bleeding risks while other herbs
that result in its sub-therapeutic concentrations pro-
mote thromboembolic events [26, 91].
The possibility of interactions is directly related to the
amount of herb being consumed and the frequency of
consumption. It is suggested that a small amount of A.
sativum as culinary uses may not be having any clinical
relevance, whereas the regular consumption of large and
therapeutic amounts of fresh A. sativum could interfere
to a considerable extent in patients under anticoagulant
therapy. The most harmful effects of interactions of
herbs with drugs arise when the latter have a narrow
therapeutic window and hence likely to produce an
acute clinical consequence. Therefore, it is imperative
that clinical studies are performed on documented herbs
to evaluate safe amounts and dose. It is also recom-
mended that when adverse reactions are experienced
with drug therapy, patients must always be queried and
encourage to report of any concomitant intake of herbal
products [44].
Conclusion and future perspectives
The present review has aimed to emphasize on the poten-
tial effects of herbs on CVD and cardiovascular drug in-
teractions. The documentation, monitoring and reporting
of evidence-based data is a critical baseline step in proper
prescribing and adequate counseling for patients. Ignor-
ance of the fact that herbal products have effects analo-
gous to conventional drugs can have severe implications
and may also result in morbidity and mortality amongstpatients. Considering the present lack of understand-
ing and dearth of data on herb-drug interactions, proper
reporting of cases, pharmacovigilance techniques, evidence-
based appraisal and regular updated systematic reviews
are imperative approaches to promote the efficiency of
drug regimens and meet therapeutic targets successfully
in patients. Therefore, it is fundamental to perform rigor-
ous clinical studies in compliance with clinical safety stan-
dards to validate therapeutic use of such herbal products
in CVD patients.
It is recommended that doctor-patient communication
and education be enhanced and that clinicians should be
more cooperative with patients to enable the reporting
of cases and should routinely inquirer about such use.
Additionally, it also important when addressing adverse
drug reactions, question patients about possible herbal
products use and not to discount long-term use of herbs
as causing side effects. Such cases should be reported to
appropriate authorities and pharmacovigilance centers.
Clinicians must also accept the fact that they should up-
date their knowledge on such kind of practice and must
be provided with adequate herb-drug interactions related
training so that they can effectively counsel their pa-
tients of any danger related to the concomitant use of
both. Consequently, due to these prevailing circum-
stances the American Herbal Products Association ad-
vices consumers to report to their treating physician the
concomitant use of herbs so that physicians are suffi-
ciently informed and can provide valuable advice [5]. It
is also suggested that herbal product(s) manufacturers
should warn their patients by incorporating into their
product label its potential to interfere with the patient’s
drug metabolism systems such as the Cytochrome P450
enzyme family. Labels in the form of cautions that pro-
hibit the use of the product in specific disease conditions
are also proposed. In addition, companies should focus
on supplying standardized extracts following intensive
quality control and/or rigorous double-blind clinical
trials.
On the other hand, once the active constituents in a
herbal product and the mechanism via which they act
are defined, a standardized quality extract must be pre-
pared for evaluating their pharmacological potentials
clinically. Therapeutic investigations must be per-
formed through well-designed, randomized, double-
blinded, placebo-controlled clinical trials involving a
significant number of subjects. It may be better to
study effects via clinical trials following good clinical
practice to increase the yield of quality results rather
than to rely on clinical studies that may bear methodo-
logical weaknesses.
It is also recommended to study the varying pheno-
types and genotypes of CYP alleles in various popula-
tions, ethnic groups, different environmental conditions
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ity as well as understanding the metabolism of natural
products and the impact of these natural products on
the CYP enzyme activities. Studying such factors in the
cytochrome P450 family will enable understanding
mechanisms clearly and this will help to better monitor
the adverse drug events of herbals in patients.
The use of in silico protein–drug interactions studies
and computer aided drug designing approach and quantum
mechanical calculations will allow predicting the mech-
anism of interaction of P450 with herbal constituents.
Wherever possible, computer aided approaches can also
be employed to explore and better describe the effects
of multi-item and polyherbal prescriptions. Last but not
least, it is important to encourage scientific meetings
and lectures regarding herb-drug interactions world-
wide to inform and educate clinicians and patients.
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